Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research

VALENCIA, Calif., Sept. 4, 2013 – Sanguine BioSciences, a biotechnology company enabling personalized medicine research, today announced that it hasREAD MORE…

Sucampo to Present Results From Four Phase 3 Studies of AMITIZA(R) (lubiprostone) for Opioid-Induced Constipation at PAINWeek 2013

BETHESDA, Md., Sept. 4, 2013 — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (“Sucampo”) will be presenting data from four separate phase 3READ MORE…

Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries

WALTHAM, Mass., Sept. 4, 2013 – Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, aREAD MORE…

Endocyte and Nihon Medi-Physics (NMP) Enter Into Exclusive License Agreement to Develop and Commercialize Companion Imaging Diagnostic Etarfolatide for Cancer in Japan

WEST LAFAYETTE, Ind. and TOKYO, Sept. 5, 2013 — Endocyte, Inc. (Nasdaq: ECYT), a biopharmaceutical company and leader in targetedREAD MORE…

Cempra’s Solithromycin Demonstrates Safety and Tolerability in Patients With Chronic Liver Disease

CHAPEL HILL, N.C., Sept. 5, 2013 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics toREAD MORE…

Cempra’s Solithromycin (CEM-101) Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration

CHAPEL HILL, N.C., Sept. 6, 2013 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics toREAD MORE…

StemCells, Inc. Publishes Comprehensive Review of Results From HuCNS-SC Clinical Trials

NEWARK, Calif., Sept. 9, 2013 — StemCells, Inc. (Nasdaq:STEM) today announced the publication of a comprehensive overview describing the therapeuticREAD MORE…

Cempra to Present Data at ICAAC on Solithromycin’s (CEM-101) Activity Against a Broad Range of Pathogens

CHAPEL HILL, N.C., Sept. 10, 2013 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics toREAD MORE…

Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer

WALTHAM, Mass., Sept. 11, 2013 – Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) hasREAD MORE…

StemCells, Inc. Announces New Preclinical Data Showing HuCNS-SC(R) Cells Preserve Visual Function by Keeping Photoreceptors Normal and Healthy

NEWARK, Calif., (September 18, 2013) – StemCells, Inc. (Nasdaq: STEM) today announced the publication of preclinical data confirming that theREAD MORE…

Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology

BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) — Sucampo AG (“SAG”), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP)READ MORE…

The Burrill Report Podcast: Developing Vaccines for the Deadliest Diseases

Some of the world’s deadliest infectious diseases have proven difficult targets for vaccines, but the nonprofit Seattle BioMed is applyingREAD MORE…

Natera and Solstas Lab Partners Enter Distribution Agreement for Non-Invasive Prenatal Test, PanoramaTM

GREENSBORO, N. C., and SAN CARLOS, Calif., September 18, 2013 – Solstas Lab Partners, one of the nation’s fastest-growing full-serviceREAD MORE…

Luminex Corporation Receives FDA and European Clearance for a New Personalized Medicine Genotyping Assay, xTAG® CYP2C19 Kit

AUSTIN, Texas, Sept. 23, 2013 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19READ MORE…

The Burrill Report Podcast: Building a Better Cancer Drug

The approvals of Seattle Genetics’ Adcetris in 2011 and Genentech’s Kadcyla this year have raised interest in antibody-drug conjugates, aREAD MORE…

New FDA Breakthrough Therapy Designation Warmly Welcomed

It has been just over a year since the Food and Drug Administration Safety and Innovation Act (FDASIA) was signedREAD MORE…

Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics

RICHMOND, Va., and SAN DIEGO, Sept. 25, 2013 – Global Genomics Group (G3) and Illumina, Inc. (NASDAQ:ILMN) today announced thatREAD MORE…

HIV Researchers Seek a Potential Cure

Academic institutes, including Seattle BioMed, are developing vaccines that will elicit antibodies against conserved sites among all HIV variants. Dr.READ MORE…

Sutro Aims to Deliver Anti-Tumor “Warheads” More Precisely

One of the big-tent biotechnology conferences opening this month focuses on a drug strategy that could be dubbed the targetedREAD MORE…

StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury

NEWARK, Calif., Oct. 2, 2013 — StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) hasREAD MORE…

Cellular Dynamics Issued U.S. Patent Covering iPSC Episomal Reprogramming

MADISON, Wis., Oct. 2, 2013 — Cellular Dynamics International (CDI) (Nasdaq:ICEL), announced today that the U.S. Patent and Trademark OfficeREAD MORE…

CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine

TUEBINGEN, Germany, Oct. 3, 2013 – CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a newREAD MORE…

Arena Pharmaceuticals and Eisai Expand Marketing and Supply Agreement for BELVIQ (lorcaserin HCl) to Include Most Countries Worldwide

SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announcedREAD MORE…

Colin Goddard, Ph.D., Joins the Endocyte Board of Directors

WEST LAFAYETTE, Ind., Nov. 7, 2013 — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small moleculeREAD MORE…

Health Insurance Innovations, Inc. Appoints Marketing Expert Jeffrey Eisenberg to Board of Directors

TAMPA, Fla., Nov. 11, 2013 — Health Insurance Innovations, Inc. (Nasdaq:HIIQ) (“HII” or “Company”), a leading developer and administrator ofREAD MORE…

Cooney/Waters and Russo Partners Launch Clearpath Health Communications

Integrated Communications Service Provides Healthcare Companies with Support Throughout Their Business and Product Lifecycles NEW YORK, Nov. 12, 2013 –READ MORE…

New England Journal of Medicine Publishes Positive Data From Clinical Trial of Novavax’ Vaccine Against H7N9 Avian Flu

ROCKVILLE, Md., Nov. 13, 2013 (GLOBE NEWSWIRE) — Novavax, Inc. (NVAX) today announced that positive clinical data for the company’sREAD MORE…

Reuters: Experimental avian flu vaccine shows promise in early trial

Nov 13 (Reuters) – The first human test of an experimental vaccine against a deadly strain of avian flu, usingREAD MORE…

Global Genomics Group (G3) to Collaborate with Metabolon on Pan-Omic GLOBAL Study to Discover Cardiovascular Disease Biomarkers and Drug Targets

RICHMOND, V.A. and RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2013 – Global Genomics Group (G3) and Metabolon today announced thatREAD MORE…

Preclinical Study Suggests That Solithromycin May Provide an Effective Antimicrobial Approach for Prevention and Treatment of Intrauterine Infections in Pregnancy

CHAPEL HILL, N.C., Nov. 18, 2013 (GLOBE NEWSWIRE) — Cempra, Inc., (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiatedREAD MORE…

Jain Foundation Signs Agreement With Cellular Dynamics to Create iPSC Lines From Patients With Muscular Dystrophies

SEATTLE and MADISON, Wis., Dec. 4, 2013 — The Jain Foundation, a non-profit organization whose mission is to cure muscularREAD MORE…

Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Neratinib Graduates from I-SPY 2 TRIAL

LOS ANGELES, Calif., Dec. 4, 2013 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical compa ny, today announcedREAD MORE…

Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia

CAMBRIDGE, Mass., Dec. 5, 2013 – Catabasis Pharmaceuticals, Inc., today announced the initiation of a Phase 2 clinical trial investigatingREAD MORE…

Apogenix’ APG350 Effectively Induces Apoptosis of Tumor Cells via TRAIL Pathway Independent of Fcγ Cross-Linking

Heidelberg, Germany, Dec. 5, 2013 – Apogenix, a clinical stage biopharmaceutical company, announced today that the data published in theREAD MORE…

The Hamner Institutes and Cellular Dynamics Collaborate to Develop In Vitro Assays Using Human iPS Cell-Derived Hepatocytes

RESEARCH TRIANGLE PARK, N.C. and MADISON, Wis., Dec. 9, 2013 (GLOBE NEWSWIRE) — The Hamner Institutes for Health Sciences todayREAD MORE…

Covagen Secures CHF 42 Million in Series B Financing

ZURICH-SCHLIEREN, Switzerland, Dec. 9, 2013 – Covagen today announced that the company has secured CHF 42 million in a tranchedREAD MORE…

Forbes: Biotech Entrepreneur’s Fortune Nearly Doubles After Strong Clinical Trials For Cancer Treatment

Alan Auerbach is the brains and leadership behind Puma Biotechnology PBYI +2.59%, a biopharma acquirer and developer of innovative cancerREAD MORE…

Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products

SAN FRANCISCO, Dec. 11, 2013 – Sutro Biopharma today announced that the company has secured $26 million in a SeriesREAD MORE…

Endocyte Enrolls First Patient in Phase 1 Study for the Small Molecule Drug Conjugate EC1456, a Folate-Targeted Tubulysin Conjugate in Advanced Solid Tumors

WEST LAFAYETTE, Ind., Dec. 12, 2013 — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in targeted small molecule drugREAD MORE…

DiagCor to Launch Natera’s Panorama™ Non-Invasive Prenatal Test in Hong Kong

SAN CARLOS, Calif.–(BUSINESS WIRE)–Natera today announced that DiagCor, a manufacturer of in-vitro diagnostic products and service provider of clinical diagnosticREAD MORE…

Fibrocell Science Chairman & CEO David Pernock Joins Board of Alliance for Regenerative Medicine

EXTON, Pa.–(BUSINESS WIRE)– Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments forREAD MORE…

CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

TÜBINGEN, Germany, 16 December 2013 – CureVac, a German clinical stage biopharmaceutical company, today announced that it has reached theREAD MORE…

Preclinical Data Support Endocyte’s Folate Receptor-Targeted Small Molecule Drug Conjugates for Treatment of Triple Negative Breast Cancer

WEST LAFAYETTE, Ind., Dec. 16, 2013 (GLOBE NEWSWIRE) — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targetedREAD MORE…

Cempra, Inc., Provides Update on Clinical Development of Solithromycin and Taksta(TM)

CHAPEL HILL, N.C., Dec. 16, 2013 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), today provided an update on the clinical developmentREAD MORE…

Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation

BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (“Sucampo”) and its development andREAD MORE…

Natera Names Susan Gross, M.D., Chief Medical Officer

SAN CARLOS, Calif. – December 20, 2013 – Natera, a leading innovator in prenatal genetic testing, today announced the additionREAD MORE…

Wall Street Journal: Nestlé in Biotech Deal to Test Foods on Human Cells

Nestlé SA, the maker of Gerber baby food and Nescafé instant coffee, is deepening its research into the link betweenREAD MORE…

Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014

BERKELEY HEIGHTS, N.J., Jan. 13, 2014 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewedREAD MORE…

Sunshine Heart Provides Corporate Update

EDEN PRAIRIE, Minn., Jan. 13, 2014 — Sunshine Heart, Inc. (Nasdaq:SSH) today provided a corporate update in advance of theREAD MORE…

Apogenix’ APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma

HEIDELBERG, Germany, Jan. 13, 2014 – Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phaseREAD MORE…

Joint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development

SOUTH PLAINFIELD, NJ, JANUARY 22, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (SIX: RO, ROG;READ MORE…

Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

WALTHAM, Mass., Jan. 23, 2014 – Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its boardREAD MORE…

Science: Historic Patent on Embryonic Stem Cells Faces Scrutiny

Opponents of the 2006 James Thomson patent say that it should be thrown out based on the same logic thatREAD MORE…

Seattle BioMed Researchers Identify Two HIV-1 Envelope Immunogens Capable of Eliciting Antibodies Associated with Vaccine Protection

Seattle, WA., January 24, 2013 — Seattle BioMed researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies whenREAD MORE…

Singapore’s First Influenza Vaccine Demonstrates Favourable Immunogenicity and Tolerability in Clinical Testing

SINGAPORE and ZURICH, January 29, 2014 — SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ — Singapore’s Agency for Science, TechnologyREAD MORE…

Bloomberg TV: A New Approach Helping Doctors Treat Heart Disease

Feb. 5 (Bloomberg) –- Sunshine Heart CEO Dave Rosa and The Chopra Foundation Founder Dr. Deepak Chopra discuss the newREAD MORE…

All Physicians in Switzerland Are Now Able to Prescribe Sucampo’s AMITIZA(R) for Chronic Idiopathic Constipation

Swiss Bundesamt fur Gesundheit (BAG) Lifts Several Key Restrictions to AMITIZA Specialty List, Increasing Patient Access BETHESDA, Md., Feb. 6,READ MORE…

Sucampo Names Peter Greenleaf Chief Executive Officer

BETHESDA, Md., February 10, 2014 – Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (“Sucampo”) today announced that Peter Greenleaf will join SucampoREAD MORE…

Cempra’s Solithromycin Demonstrates No QT Effects in Thorough QT Study

CHAPEL HILL, N.C., Feb. 11, 2014 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics toREAD MORE…

Arena Pharmaceuticals Announces Filing for Marketing Authorization of BELVIQ(R) (lorcaserin HCl) in Brazil

— Eisai’s Filing for Approval of BELVIQ as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to ArenaREAD MORE…

StemCells, Inc. Announces Completion of the First of Two Cohorts in its Dry Age-Related Macular Degeneration Trial

NEWARK, Calif., Feb. 12, 2014 — StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first ofREAD MORE…

Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

REG2 Extends Regado’s Next-Generation Anticoagulation Therapy Franchise as Phase 3 REGULATE-PCI Clinical Trial of REG1 Advances BASKING RIDGE, N.J., Feb.READ MORE…

Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

WALTHAM, Mass., Feb. 13, 2014 – Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD)READ MORE…

Global Genomics Group (G3) Completes Patient Enrollment Of Discovery Cohort In GLOBAL Study Ahead Of Schedule

RICHMOND, Va., Feb. 13, 2014 – Global Genomics Group (G3) today announced that it has completed enrollment of the 5,000-patientREAD MORE…

Puma Biotechnology Closes $138 Million Public Offering of Common Stock

LOS ANGELES, Calif., Feb. 14, 2014 — Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closingREAD MORE…

Global Genomics Group (G3) And Quintiles, Inc. (Q) Collaborate On Cross-Functional Pan-Omic Study Of Biomarkers And Drug Target Discovery For Cardiovascular Diseases

February 19, 2014 — Global Genomics Group (G3) and Quintiles today announced that they will collaborate to investigate novel biomarkersREAD MORE…

Cempra Initiates Solithromycin Pediatric Program

First Patient Dosed in Biomedical Advanced Research and Development Authority (BARDA)-Funded Phase 1 Study CHAPEL HILL, N.C., Feb. 20, 2014READ MORE…

OrbusNeich Initiates HARMONEE Study in Japan to Evaluate the COMBO™ Dual Therapy Stent

Company Initiates Joint U.S. and Japanese Registration Trial HONG KONG, Feb. 26, 2014 – OrbusNeich today announced that patient enrollmentREAD MORE…

Catabasis Names Andrew Nichols, Ph.D., Vice President of Research

CAMBRIDGE, Mass., Feb 26, 2014 – Catabasis Pharmaceuticals Inc. today announced that it has named Andrew Nichols, Ph.D., to theREAD MORE…

Global Genomics Group (G3) and Caprion to Partner on GLOBAL Study to Identify Cardiovascular Disease Biomarkers and Drug Targets

RICHMOND, Va. and MONTREAL, Feb. 26, 2014 — Global Genomics Group (G3) and Caprion Proteomics, Inc., today announced that theyREAD MORE…

Xconomy: Cellular Dynamics, Seizing the Present, Turns Stem Cells into Cash

Stories like Cellular Dynamics don’t grab venture capitalists in Boston or the San Francisco Bay Area. Stem cell biology asREAD MORE…

Financial Times: Reluctant star of stem cell research

America’s most celebrated bioscientist around the turn of this century was James Thomson. He was the face of the newREAD MORE…

S1 Biopharma Prepares to Initiate Phase 2a Clinical Trial for Low Male Sexual Desire

Orexa will be the first drug ever to enter clinical trials for male HSDD JERSEY CITY, N.J., March 3, 2014READ MORE…

Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and ‘Step Into Spring’ Program Sponsor for 2014

Partnership Reflects Continued Commitment to Innovation and Cultural Collaboration BETHESDA, Md. and WASHINGTON, March 4, 2014 — Sucampo Pharmaceuticals, Inc.READ MORE…

FDA Designates Regado’s REG1 in PCI as a Fast Track Development Program

Enrollment in the Phase 3 REGULATE-PCI Trial is Ongoing for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention BASKING RIDGE,READ MORE…

Seattle BioMed Awarded $9.8 Million Grant from the National Institutes of Health to Develop Vaccine Against HIV/AIDS

Multi-center collaboration aims to advance neutralizing antibody research from preclinical to clinical trials Seattle, WA, March 10, 2013 — SeattleREAD MORE…

CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize

RNActive® Vaccines Offer Excellent Conditions for Cost-Effective Worldwide Distribution TÜBINGEN, Germany/BRUSSELS, Belgium, 10 March 2014 – CureVac, a German clinicalREAD MORE…

Exosome Diagnostics Raises $27 Million in Series B Financing

New York City — March 11, 2014 — Exosome Diagnostics today announced the initial close of its Series B financingREAD MORE…

GEN: Harnessing the Power of Exosomes

These lipid nanovesicles are garnering attention in diagnostics, for drug delivery, and as research tools. Exosomes are lipid nanovesicles, onREAD MORE…

Novira Names Christian S. Schade Chief Executive Officer

DOYLESTOWN, Pa., March 19, 2014 — Novira Therapeutics, Inc., today announced that Christian S. Schade has been named Chief ExecutiveREAD MORE…

ECOG-ACRIN Opens Phase III Trial of Syndax’s Entinostat in Advanced Breast Cancer

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in itsREAD MORE…

Cellular Dynamics Announces Presentations at the SOT Annual Meeting Highlighting Use of iPSC-Derived Human Cells for Environmental Toxicology and Drug Toxicity Testing

MADISON, Wis., March 21, 2014 — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced scientific presentations at the Society ofREAD MORE…

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (IntravenousREAD MORE…

Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival

Conference Call/Webcast at 9 a.m. EDT Today WEST LAFAYETTE, Ind., March 21, 2014 — Endocyte, Inc. (Nasdaq:ECYT) today announced resultsREAD MORE…

Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury

Study Suggests Clinical Uses of Solithromycin Beyond Bacterial Infections Presentation at the American Thoracic Society 2014 International Conference CHAPEL HILL,READ MORE…

Scioderm Completes Enrollment of Phase 2b Study of SD-101, a Novel Topical Therapy for Patients with Epidermolysis Bullosa

Durham, N.C. (April 1, 2014) — Scioderm, Inc. today announced it has completed enrollment of its Phase 2b study (SD-003)READ MORE…

Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

REGULATE-PCI Opened to “All Comers” PCI Population BASKING RIDGE, N.J., April 2, 2014 /PRNewswire/ — Regado Biosciences, Inc. (Nasdaq: RGDO),READ MORE…

Cempra’s Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity

Cempra, Inc. to Present Late-Breaker on Solithromycin’s Anti-NASH Effects in an Animal Model at DDW 2014 CHAPEL HILL, N.C., AprilREAD MORE…

Seattle BioMed Researchers Identify Innate Immune Response to Malaria Parasite Liver Stage Infection

Preclinical Study Published in Cell Reports Identifies Key Signaling Pathways in Innate Immune Sensing of Malaria Parasite During Liver StageREAD MORE…

Endocyte Announces Presentations at AACR Annual Meeting 2014

Data for Endocyte’s Folate Receptor (FR)-Targeting Folate-Tubulysin Conjugate, EC1456, and Prostate-Specific Membrane Antigen (PSMA)-Targeted Tubulysin, SMDC, EC1169, to be PresentedREAD MORE…

Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL

Neratinib Graduates from I-SPY 2 TRIAL LOS ANGELES, Calif., April 7, 2014 Puma Biotechnology, Inc. (NYSE: PBYI), a development stageREAD MORE…

Regado Biosciences Announces Pricing of Public Offering of Common Stock

BASKING RIDGE, N.J., April 11, 2014 /PRNewswire/ — Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previouslyREAD MORE…

Arena Pharmaceuticals Reports Eisai’s Launch of National Television Advertising Campaign for BELVIQ (lorcaserin HCl) CIV for Chronic Weight Management

SAN DIEGO, April 14, 2014 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched aREAD MORE…

Epirus Closes $36 Million Series B Financing

BOSTON, April 16, 2014 – Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercializationREAD MORE…

Epirus and Zalicus Announce Merger Agreement

• Merger will create a publicly traded, global biosimilar enterprise focused on improving patient access to important medicines • EpirusREAD MORE…

Regado Biosciences Announces Closing of Public Offering of Common Stock

BASKING RIDGE, N.J., April 16, 2014 /PRNewswire/ — Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previouslyREAD MORE…

MIT Technology Review: Stem-Cell Treatment for Blindness Moving Through Patient Testing

Advanced Cell Technology is testing a stem-cell treatment for blindness that could preserve vision and potentially reverse vision loss. ClickREAD MORE…

StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial

Interim Data to be Presented at Upcoming American Spinal Injury Association Conference NEWARK, Calif., April 17, 2014 (GLOBE NEWSWIRE) —READ MORE…

BioWorld Today: Scioderm seeks fast track with breakthrough drug for rare skin disorder

“The worst disease you’ve never heard of.” That’s how patient advocacy and nonprofit group Debra (Dystrophic Epidermolysis Bullosa Research AssociationREAD MORE…

Data from Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody against CGRP for the Prevention of Migraine, to be Presented at American Academy of Neurology Meeting

BOTHELL, Wash., April 23rd , 2014 – Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director,READ MORE…

Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine’s 100 Most Influential People in the World

Dr. Lanza and the other TIME 100 will be honored at a Gala Event on Tuesday April 29, 2014 MARLBOROUGH,READ MORE…

Wired: Mers vaccine helps mice fight off deadly virus

Today, there is no real treatment or vaccine that can tackle Middle East Respiratory Syndrome (Mers), a virus that wasREAD MORE…

Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal

BETHESDA, Md., May 6, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that itsREAD MORE…

Cempra Presents Late-Breaker on Solithromycin’s Anti NASH Effects in an Animal Model at DDW 2014

CHAPEL HILL, N.C., May 6, 2014 (GLOBE NEWSWIRE) — Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycinREAD MORE…

Cempra to Present Data on Solithromycin at ECCMID Highlighting Potential New Indications, Safety and Activity Spectrum

CHAPEL HILL, N.C., May 9, 2014 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP) today announced that it will present data atREAD MORE…

Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ(R) (lorcaserin HCl) CIV by 50%

— Expansion to Approximately 600 Sales Specialists Follows Initiation of National Television Advertising Campaign — — Access to Reimbursement CoverageREAD MORE…

GenomeWeb: CombiMatrix Prepares New Test Offerings as Reproductive Health Services Drive up Revenues

NEW YORK (GenomeWeb) – CombiMatrix is developing two new tests that will expand its place in the reproductive health market,READ MORE…

Financial Times: Genetic treatment for muscular dystrophy

Promising treatments for specific subgroups of inherited disease are emerging as genetic technology makes it possible to pinpoint the DNAREAD MORE…

GEN: Small Molecules, Big Possibilities

Selective, targeted small molecule drug candidates are moving through the clinical development pipeline in a range of disease indications. WhileREAD MORE…

Regado Biosciences Appoints Nicholas Pelliccione, Ph.D., Senior Vice President of Regulatory Affairs and Quality Assurance and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

BASKING RIDGE, N.J., May 19, 2014 /PRNewswire/ — Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the PhaseREAD MORE…

StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury

Significant Sensory Gains Observed in Additional Patients NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced todayREAD MORE…

StemCells, Inc. Advances Clinical Trial in Age-Related Macular Degeneration to Final Cohort

Phase I/II AMD Trial on Track to Complete Enrollment in June NEWARK, Calif., May 22, 2014 (GLOBE NEWSWIRE) — StemCells,READ MORE…

PTC Therapeutics Receives Positive Opinion from CHMP for Translarna™ (Ataluren)

– The first treatment for the underlying cause of Duchenne muscular dystrophy – SOUTH PLAINFIELD, NJ – May 23, 2014READ MORE…

Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. – May 27, 2014 – Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will beREAD MORE…

OC Register: CombiMatrix’s new genetic testing method may help solve pregnancy losses

Company wants its method to be the standard for analyzing cases of women with multiple miscarriages. At CombiMatrix Corp., aREAD MORE…

Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients

Single Largest Prospective Pan-Omic Study to Identify Key Biomarkers and Central Therapeutic Targets for Cardiovascular Diseases Has Completed Enrollment RICHMOND,READ MORE…

Seattle BioMed’s Researchers Develop Vaccine Candidate Using Genetically Engineered Malaria Parasite

Study published in Molecular Therapy provides path forward for highly protective malaria vaccine Seattle, WA., May 29, 2014 — SeattleREAD MORE…

Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases

SAN DIEGO, June 3, 2014 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in an investigational Phase 1b clinicalREAD MORE…

StemCells, Inc. Strengthens Senior Executive Team

NEWARK, Calif., June 17, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today one promotion and three new appointments toREAD MORE…

Cempra, Inc. to Present at JMP Securities Healthcare Conference

CHAPEL HILL, N.C., June 17, 2014 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executiveREAD MORE…

Endocyte Regains Worldwide Rights to Vintafolide

WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) — Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwideREAD MORE…

Debiopharm Group Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections

Lausanne, Switzerland – June 19, 2014 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmetREAD MORE…

StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial

NEWARK, CA, June 19, 2014 (GLOBE NEWSWIRE) – StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinicalREAD MORE…

StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry Age-Related Macular Degeneration Trial

NEWARK, Calif., June 20, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) yesterday announced that based on positive interim results, itREAD MORE…

The EMA and FDA Grant Orphan Drug Designation to Pharnext’s PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A

PARIS, June 23, 2014 – Pharnext SAS today announced that the European Medicines Agency (EMA) and the U.S. Food andREAD MORE…

StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the 2014 BIO International Convention

NEWARK, CA, June 23, 2014 (GLOBE NEWSWIRE) – StemCells, Inc. (Nasdaq:STEM) announced today that president and CEO Martin McGlynn will beREAD MORE…

Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President and Chief Executive Officer

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment ofREAD MORE…

Debiopharm Group and TCG Lifesciences Ltd. announce successful completion of first phase of research collaboration on discovery of novel antibiotics

Lausanne, Switzerland and Kolkata, India – June 24 2014 – Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on theREAD MORE…

Data from Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society

BOTHELL, Wash., June 26, 2014 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Debiopharm Group and Nobelex Biotech Start Two Collaborations on Development of New Antibiotics Against N. Gonorrhoeae and Enteric Species

Lausanne, Switzerland and Toronto, Canada – June 26, 2014 – Debiopharm Group™ (Debiopharm), a Switzerland-based global biopharmaceutical company developing prescriptionREAD MORE…

Alder BioPharmaceuticals Added to Russell 3000(R) Index

BOTHELL, Wash., June 27, 2014 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc., (“Alder”) (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibodyREAD MORE…

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

TÜBINGEN, Germany, July 1, 2014 – CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive licenseREAD MORE…

Advanced Cell Technology, Inc. Announces Paul K. Wotton Ph.D. Recognized as Ernst & Young (EY) 2014 Entrepreneur of the Year™ for New Jersey Region

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”) (OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that PaulREAD MORE…

Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it hasREAD MORE…

StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors

NEWARK, Calif., July 7, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today the appointment of Alan Trounson, Ph.D. toREAD MORE…

Cellular Dynamics Awarded Patents Covering Derivation of Pluripotent Stem Cells From Fresh or Banked Human Blood Samples

MADISON, Wis., July 9, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL), today announced that the U.S. PatentREAD MORE…

CombiMatrix offers answers for women who have had multiple miscarriages

It’s a little discussed fact that many pregnancies end in miscarriage – and it can be hard to understand why. CombiMatrix,READ MORE…

StemCells, Inc. Announces Proposed $20 Million Offering

NEWARK, Calif., July 15, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM), today announced its intent to offer and sell 11,299,435READ MORE…

Combimatrix’s Pediatric Development Disorders Analysis Test Granted Conditional Approval from New York State Department of Health

IRVINE, California, July 15, 2014 (GLOBE NEWSWIRE) – CombiMatrix Corporation (NASDAQ: CBMX), a molecular diagnostics company performing DNA-based testing servicesREAD MORE…

Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain

SAN FRANCISCO, Calif., July 16 – Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecularREAD MORE…

Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ(R) (lorcaserin HCl) in Israel

SAN DIEGO, July 21, 2014 — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH,READ MORE…

Candid Advice For Cash-Strapped Startups From A Biotech VC

July 21, 2014 By Josh Baxt, BioSpace.com Exclusive Story In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners runREAD MORE…

CombiMatrix Signs Contract With Stratose Networks Division, One of the Largest Directly-Managed PPO Networks in U.S.

IRVINE, Calif., July 22, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders andREAD MORE…

Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)

BETHESDA, Maryland and ABINGDON, Oxfordshire, July 23, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company,READ MORE…

Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group

EXTON, Pa.–(BUSINESS WIRE)– Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments forREAD MORE…

PTC Therapeutics CFO: Positive News on Translarna Just the Start

Click here to watch the video  

Check out Russo Partners’ AdCom Jeopardy panel at the BIO International Convention 2014

Click here to check the Jeopardy out

Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity

WOODCLIFF LAKE, N.J. and SAN DIEGO, July 30, 2014 /PRNewswire/ — Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced todayREAD MORE…

Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

WALTHAM, Mass.- July 30, 2014 – Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studiesREAD MORE…

CombiMatrix’s SNP-Based Miscarriage Analysis Test Granted Conditional Approval From New York State Department of Health

IRVINE, Calif., July 31, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancerREAD MORE…

PTC THERAPEUTICS RECEIVES CONDITIONAL APPROVAL IN THE EUROPEAN UNION FOR TRANSLARNA™ FOR THE TREATMENT OF NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY

SOUTH PLAINFIELD, NJ – August 4, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission hasREAD MORE…

Exosome Diagnostics Announces Appointment of Thomas McLain as Chief Executive Officer

CAMBRIDGE, Mass. – Aug. 4, 2014 – Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced theREAD MORE…

NIH Grant Co-Awarded to Seattle BioMed Scientist and Collaborators for Groundbreaking Technological Advancement in Biological Research

SEATTLE, Aug. 5, 2014 (GLOBE NEWSWIRE) — Professor John Aitchison (of Seattle BioMed and Institute for Systems Biology) is aREAD MORE…

Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

CHAPEL HILL, N.C., Aug. 12, 2014 (GLOBE NEWSWIRE) — Cempra, Inc., (Nasdaq:CEMP) today announced the initiation of a Phase 3READ MORE…

Tips for Navigating Prenatal Genetic Testing

Tips for Navigating Prenatal Genetic Testing August 14, 2014 Sarah Bruyn Jones Original link  Rapid advancements in genetic testing haveREAD MORE…

Chromosomal Microarrays for Prenatal Testing: Interview with CombiMatrix CEO Mark McDonough

While there has admittedly been a lot of hype around genetics, most people may not realize that there are many instancesREAD MORE…

CombiMatrix CEO Mark McDonough and NFL Networks/CBS NFL Analyst Solomon Wilcots team up at company’s sales meeting in Chicago

Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone

BETHESDA, Md., Aug. 21, 2014– Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that its subsidiary, SucampoREAD MORE…

Cellular Dynamics Awarded U.S. Patent Covering Automated Production of All Human Pluripotent Stem Cells

MADISON, Wis., Aug. 28, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL) today announced that the U.S. Patent andREAD MORE…

Arena Pharmaceuticals’ APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug AdministrationREAD MORE…

Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab

BOTHELL, Wash., Sept. 2, 2014 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage company developing antibody therapeutics, today announcedREAD MORE…

Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014

LOS ANGELES, Calif., Sept. 3, 2014 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that dataREAD MORE…

Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies

DOYLESTOWN, Pa., September 4, 2014 – Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatmentREAD MORE…

Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA

Lausanne, Switzerland – September 4, 2014 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmetREAD MORE…

Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member

SAN FRANCISCO, Sept. 9, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generationREAD MORE…

Cempra Milestone Highlights Experimental Antibiotic’s Potential

Cempra Pharmaceuticals’ (NASDAQ: CEMP) efforts to bring patients a next-generation antibiotic that could help address drug-resistant bacteria now has a boostREAD MORE…

Scioderm, Inc. to Present Data from Phase 2b Study of ZorblisaTM (SD-101) at the debra International Congress

Durham, N.C. (September 9, 2014) — Scioderm, Inc., today announced Dr. Robert Ryan, president and chief executive officer, will presentREAD MORE…

PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, NJ – September 9, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment ofREAD MORE…

CombiMatrix featured in Genetic Engineering and Biotechnology News

Honing Prenatal Screening Tests Genetic testing of cell-free fetal DNA moves the bar on screening accuracy. Prenatal screening for DownREAD MORE…

Gaumard® Scientific Completes First U.S. Installations of Victoria™ Birthing Simulator

MIAMI, Sept. 15, 2014 /PRNewswire/ — Gaumard Scientific Company today announced completion of the first U.S. installations of its new Victoria birthing simulator. TheREAD MORE…

Gaumard Scientific, a South Florida Medical Simulation Company Quietly Becomes a Force in Industry

Miami Herald Nancy Dahlberg Sep 14, 2014 Christopher Jorge isn’t a doctor, but that’s not stopping Victoria. “The baby’s coming,READ MORE…

CombiMatrix featured in GEN: Microarray Testing for Unmet Needs

Genetic Engineering and Biotechnology News Gail Dutton Sep 15, 2014 CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to theREAD MORE…

Gaumard Scienfitic, a Miami-based medical simulation company conceives hyper-realistic birthing simulator

South Florida Business Journal Celia Ampel Sep 15, 2014 Newly minted medical students at the University of Miami and acrossREAD MORE…

Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument

Lausanne, Switzerland – September 17, 2014 – Debiopharm Diagnostics, part of Debiopharm Group™, is proud to congratulate Biocartis commitment in shipping itsREAD MORE…

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

SAN FRANCISCO, Sept. 17, 2014 – Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and theREAD MORE…

PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the additionREAD MORE…

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

INGELHEIM and TUBINGEN, Germany, and RIDGEFIELD, Conn., Sept. 18, 2014 /PRNewswire/ — Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleicREAD MORE…

FierceBiotech names Sutro Biopharma as one of its “Fierce 15” Biotech Companies of 2014

SAN FRANCISCO, Sept. 22, 2014 /PRNewswire/ — Sutro Biopharma today announced that it has been named by FierceBiotech as one ofREAD MORE…

Gaumard® Scientific Says NCSBN National Study Provides Strong Support for Use of Patient Simulators in Nursing Education

MIAMI, Sept. 22, 2014 /PRNewswire/ — Gaumard Scientific Company today commented on the recent publication of the National Council of State Boards of Nursing’sREAD MORE…

EPIRUS Announces Positive 58 Week Follow Up Data for BOW015 for treatment of Rheumatoid Arthritis

BOSTON, September 23, 2014 – EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global developmentREAD MORE…

SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant

SAN FRANCISCO, Sept. 23, 2014 — SiteOne Therapeutics Inc. today announced the completion of its initial round of equity financing.READ MORE…

Advanced Cell Technology Announces Final Patient Treated in Stargardt’s Macular Degeneration Phase 1 Trial in the United Kingdom

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTCD), a leader in the field of regenerative ophthalmology, announced today that it hasREAD MORE…

EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China

BOSTON, September 25, 2014 – EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global developmentREAD MORE…

Presented by the Japanese Cancer Association and Debiopharm Group™, the ‘JCA-Mauvernay Award 2014’ goes to Doctors Hara and Shibata

Lausanne, Switzerland – September 26, 2014 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmetREAD MORE…

Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte’s Vintafolide

WEST LAFAYETTE, Ind., Sept. 27, 2014 (GLOBE NEWSWIRE) — Endocyte, Inc. (Nasdaq:ECYT), today announced that the small molecule drug conjugateREAD MORE…

Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer

LOS ANGELES, Calif., Sept. 29, 2014 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that positiveREAD MORE…

Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation

BETHESDA, Md., Sept. 29, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP) and its development and commercialization partner, Takeda Pharmaceuticals (Takeda), today announced the launchREAD MORE…

Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Sept. 29, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focusedREAD MORE…

Catalyst Pharma’s lead drug succeeds in late-stage study

Sept 29 (Reuters) – Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated withREAD MORE…

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Toronto, Canada and Lausanne, Switzerland – September 30, 2014 – Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatmentREAD MORE…

Sucampo goes all-in on Amitiza with new DTC effort

Medical Marketing & Media Sep 30, 2014 For the majority of drugs, end-of-lifecycle planning usually involves a reining-in of marketingREAD MORE…

Gaumard® Scientific Continues U.S. Roll-Out of Victoria™ Birthing Simulator with Installations in New York, Texas and Louisiana

MIAMI, Oct. 1, 2014 – Gaumard Scientific Company today provided an update on the U.S. roll-out of its Victoria birthingREAD MORE…

StemCells, Inc. to Participate at the 2014 Stem Cell Meeting on the Mesa

NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn willREAD MORE…

StemCells, Inc. featured in The Scientist: Eyes on the Prize

The Scientist  Oct 1, 2014 A handful of stem cell therapeutics for vision disorders are showing promise in early-stage trials,READ MORE…

Catalyst Pharmaceuticals to Present at 13th Annual BIO Investor Forum

CORAL GABLES, Fla., Oct. 2, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focusedREAD MORE…

Migraine drug shows positive results, says Alder Biopharma

Bothell-based Alder Biopharmaceuticals is one step closer to commercializing a treatment for migraine prevention, according to results of a PhaseREAD MORE…

Sunshine Heart’s C-Pulse® System Feasibility Study Data Published in JACC

EDEN PRAIRIE, MN, Oct. 7, 2014 — Sunshine Heart, Inc. (NASDAQ: SSH) today announced the results of its feasibility studyREAD MORE…

StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury

NEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development ofREAD MORE…

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Lausanne, Switzerland – October 07, 2014 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmetREAD MORE…

CombiMatrix Reports Preliminary Growth in Prenatal Microarray Testing Volumes of 71% and 64% for the Third Quarter and Year-to-Date, Respectively

IRVINE, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatalREAD MORE…

Catalyst Pharmaceuticals to Present Top-Line Safety and Efficacy Results From Phase 3 Firdapse Trial at 139th Annual Meeting of the American Neurological Association

CORAL GABLES, Fla., Oct. 8, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focusedREAD MORE…

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA

BETHESDA, Md., Oct. 9, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo, R-Tech Ueno, Ltd. (RTU), Takeda PharmaceuticalREAD MORE…

REGADO BIOSCIENCES APPOINTS MICHAEL A. METZGER CEO

Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post ofREAD MORE…

Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting

BETHESDA, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Data to be Presented at ASHG 2014 Show That Miscarriage Analysis by Chromosomal Microarray Yields a Successful Result in More Than 85% of Cases

IRVINE, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatalREAD MORE…

Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda

BETHESDA, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9,READ MORE…

Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects

Gaithersburg, MD (October 14, 2014)–/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticleREAD MORE…

ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration

Phase 1/2 Clinical Trials of RPE Cells for the Treatment of Dry Age-Related Macular Degeneration andStargardt’s Macular Degeneration Show Positive LongREAD MORE…

Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies

Gaithersburg, MD – October 15, 2014 – Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company focused on the discovery, developmentREAD MORE…

Sacred Heart University School of Nursing Selects Gaumard® Scientific’s Victoria™ for Use in Nursing Simulation & Clinical Skills Laboratories

FAIRFIELD, Conn., and MIAMI, Oct. 15, 2014 /PRNewswire/ — The Sacred Heart University School of Nursing and Gaumard Scientific todayREAD MORE…

Updated Chordoma Data From Phase 1 Study of GI-6301 Presented at 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting

BERLIN, GERMANY–(Marketwired – October 17, 2014) – GlobeImmune, Inc., today announced that updated results from eleven chordoma patients in theREAD MORE…

Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced theREAD MORE…

Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)

BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, and Takeda Pharmaceutical CompanyREAD MORE…

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

SOUTH SAN FRANCISCO, Oct 23, 2014 – Sutro Biopharma today announced it has entered into a strategic collaboration and optionREAD MORE…

Gaumard® Scientific Installs Victoria™ Birthing Simulator at Health Care Educational Facilities in Colorado and Michigan

MIAMI, Oct. 23, 2014 – Gaumard Scientific Company today announced it has completed installations of the Victoria birthing simulator atREAD MORE…

Sucampo Solidifies Leadership Team With Additions of CSO and Heads of Business Development, Regulatory Affairs

BETHESDA, Md., Oct. 23, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced three executive appointments that expandREAD MORE…

Device shows promise for heart-failure patients

Heart failure is characterized by a heart muscle that is weak, stretched out, and flabby, and therefore unable to pumpREAD MORE…

Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia

Gaithersburg, MD (October 27, 2014) – Novavax, Inc. (NASDAQ: NVAX) today announced that Gale Smith, Ph.D., Vice President of Vaccine DevelopmentREAD MORE…

Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine

CORAL GABLES, Fla., Oct. 27, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focusedREAD MORE…

Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and Reimbursement

CORAL GABLES, Fla., Oct. 28, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovativeREAD MORE…

Apogenix – Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research

Heidelberg, Germany, Oct. 28, 2014 – Apogenix, a clinical stage biopharmaceutical company, announced today that the final data of theREAD MORE…

PTC Therapeutics Expands Access For Translarna™ (Ataluren)

SOUTH PLAINFIELD, N.J., Nov. 3, 2014 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been approved to beREAD MORE…

Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit

CORAL GABLES, Fla., Nov. 4, 2014 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals or the Company), aREAD MORE…

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development

CALGARY, Nov. 3, 2014  /CNW/ –  Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinicalREAD MORE…

Baylor University School of Nursing Expands Sim Lab’s Line-Up of Gaumard® Scientific Products with Addition of Victoria™, Industry’s Most Advanced Birthing Simulator

MIAMI, Nov. 5, 2014 /PRNewswire/ — Gaumard Scientific Company today reported that the Baylor University Louise Herrington School of Nursing has added the industry’s most advancedREAD MORE…

StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results

NEWARK, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), which pioneered the discovery and development of HuCNS-SC®cells, a proprietary population of highlyREAD MORE…

Great Basin Appoints Jeffrey Rona as Chief Financial Officer

SALT LAKE CITY, Nov. 5, 2014 /PRNewswire/ — Great Basin Scientific, Inc., (NASDAQ: GBSN), a commercial-stage molecular diagnostics company, today announced that, asREAD MORE…

Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa

Gaithersburg, MD (November 7, 2014) – Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development andREAD MORE…

Novira Therapeutics Announces Presentation Of Phase 1a Safety And Pharmacokinetic Data For NVR 3-778

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV)READ MORE…

Advanced Cell Technology Changes Name to Ocata Therapeutics

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc.,READ MORE…

Data From EPIRUS’ Phase 3 Study Of BOW015, A Biosimilar Infliximab, To Be Presented As A Late Breaking Poster At The American College Of Rheumatology Annual Meeting

EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announcedREAD MORE…

Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of the Phase III study (Study 3002) of once-daily Envarsus® XR demonstrating non-inferiorityREAD MORE…

Cellular Dynamics and Northwestern University Take First Steps Toward Rebuilding an Organ Using Manufactured Human Cells

Cutting-edge Study Uses iPSC-derived Cells to Coat Blood Vessels in Kidney Scaffolds MADISON, WIS., November 18, 2014 — Cellular DynamicsREAD MORE…

Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board

DOYLESTOWN, Pa., November 18, 2014 – Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatmentREAD MORE…

Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress

SALT LAKE CITY, Nov. 18, 2014 /PRNewswire/ — Great Basin Scientific, Inc. GBSN, +3.62% a molecular diagnostics company, today announced that the management willREAD MORE…

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona

Lausanne, Switzerland – November 18, 2014 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs along with companionREAD MORE…

International Stem Cell Corporation to Present Preclinical Parkinson’s Disease Data at Neuroscience 2014

CARLSBAD, CA–(November 18, 2014) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell basedREAD MORE…

Gaumard® Scientific Reports Latest U.S. Installations of Victoria™ Birthing Simulator as Part of Nationwide Roll-Out

MIAMI, Nov. 19, 2014 – Gaumard Scientific Company today reported the latest installations of its Victoria™ birthing simulator as part of the nationwideREAD MORE…

Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies

CHAPEL HILL, N.C., Nov. 19, 2014 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medicalREAD MORE…

Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation from the European Medicines Agency

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc., (OTCBB:OCAT) today announced that it has been granted Advanced Therapy Medicinal Product (ATMP) designation forREAD MORE…

Gaumard® Scientific to Showcase Trauma HAL®, the Battlefield Trauma Patient Simulator, at I/ITSEC 2014

MIAMI, Nov. 26, 2014 /PRNewswire/ — Gaumard Scientific Company today announced it will showcase Trauma HAL and Pediatric HALat I/ITSEC 2014, which will take place Dec. 1-5 in Orlando, Fla. TheREAD MORE…

EPIRUS Biopharmaceuticals Remicade® Biosimilar, Infimab ™, Launches in India

BOSTON, MA – December 2, 2014 – EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on theREAD MORE…

PTC Therapeutics Announces Launch of Translarna™ (ataluren) in Germany

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) is now commercially available to patients in Germany, the first countryREAD MORE…

Pharnext announces the nomination of Michel de Rosen, a Pharmaceutical and Biotechnology Industry Leader, to its Board of Directors

PARIS, Dec. 9, 2014 – Pharnext SAS, today announced the nomination of Michel de Rosen to its board of directors. READ MORE…

Great Basin Initiates Clinical Trial for Staph ID/R Molecular Diagnostic Test

SALT LAKE CITY, Dec. 10, 2014 /PRNewswire/ — Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today announced it has initiated aREAD MORE…

Simulation Centers at Hospitals and Nursing Schools Select Gaumard® Scientific’s Victoria™ Birthing Simulator

MIAMI, Dec. 11, 2014 /PRNewswire/ — Gaumard Scientific Company today provided an update on its launch of the Victoria birthing simulator. The latest U.S. installationREAD MORE…

Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio

LOS ANGELES, Calif., Dec. 12, 2014 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that interimREAD MORE…

Great Basin Appoints New Board Members

Salt Lake City, Dec 16, 2014 – Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, today welcomed RonaldREAD MORE…

CombiMatrix Launches Targeted Array for Prenatal Analysis

IRVINE, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatalREAD MORE…

Alder BioPharmaceuticals Announces Addition to NASDAQ Biotechnology Index

BOTHELL, Wash., December 16, 2014 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics forREAD MORE…

Reuters: Pharnext drug shows promise in neurological disease with no treatment

(Reuters) – Using technology gleaned from the mapping of the human genome, privately held French drug developer Pharnext SAS isREAD MORE…

Cempra Announces Positive Topline Phase 3 Clinical Results for Oral Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia

CHAPEL HILL, N.C., Jan. 4, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face ofREAD MORE…

Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer

CORAL GABLES, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focusedREAD MORE…

Sunshine Heart Appoints Claudia Drayton as Chief Financial Officer

EDEN PRAIRIE, Minn., Jan. 5, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the appointment of Claudia DraytonREAD MORE…

Scioderm Appoints Ian A. W. Howes Chief Financial Officer

Durham, N.C. (January 6, 2015) — Scioderm, Inc., today announced the appointment of Ian A.W. Howes to the position ofREAD MORE…

Gaumard® Scientific to Feature Comprehensive Line-Up of Innovative Patient Simulators for Health Care Education at IMSH

MIAMI, Jan. 6, 2015 /PRNewswire/ — Gaumard Scientific Company today unveiled its comprehensive line-up of innovative patient simulators that will be featured at the InternationalREAD MORE…

Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases

SAN DIEGO, Jan. 7, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from a Phase 1b multiple ascending doseREAD MORE…

Pharnext’s Pleotherapy Shows Synergistic Effects with PXT-864 in Alzheimer’s Disease through Preclinical Data Published in Nature’s Scientific Reports

PARIS, Jan. 8, 2015 – Pharnext SAS today announced the publication of preclinical results in Nature’s Scientific Reports for itsREAD MORE…

FDA Grants Fast Track Designation to Debiopharm Group’s Antibiotic Debio 1450

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) granted Fast Track designation toREAD MORE…

Gaumard® Scientific Reports Latest U.S. Installations of Victoria™ Birthing Simulator

MIAMI, Jan. 9, 2015 /PRNewswire/ — Gaumard Scientific Company today provided an update on installations of the Victoria birthing simulator  atREAD MORE…

Cord Blood Registry and Cellular Dynamics International Announce Collaboration to Reprogram Newborn Stem Cells into Induced Pluripotent Stem Cells

SAN BRUNO, Calif. and MADISON, Wis., Jan. 13, 2015 /PRNewswire/ — Cord Blood Registry® (CBR®) and Cellular Dynamics International (NASDAQ:READ MORE…

CombiMatrix Names Karen Warner, RN, Vice President of Reimbursement

IRVINE, Calif., Jan. 20, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatalREAD MORE…

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

LEXINGTON, Mass. and BANGALORE, India, Jan. 21, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on theREAD MORE…

International Stem Cell Corporation to Conduct Parkinson’s Disease Clinical Study in Australia

CARLSBAD, CA–(Marketwired – January 29, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell basedREAD MORE…

Gaumard Scientific Reports on the Rapid Pace of U.S. Installations of Victoria for the Start of 2015

MIAMI, Jan. 29, 2015 /PRNewswire/ — Gaumard(R) Scientific Company today provided an update on installations of the Victoria(TM) birthing simulator at U.S. health care and educationalREAD MORE…

Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO

BETHESDA, Md., Jan. 30, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the appointment of Andrew Smith, FCMA,READ MORE…

Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Feb. 2, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focusedREAD MORE…

Cellular Dynamics Manufactures cGMP HLA “Superdonor” Stem Cell Lines to Enable Cell Therapy With Genetic Matching

MADISON, Wis., Feb. 9, 2015 (GLOBE NEWSWIRE) — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced that it has manufactured,READ MORE…

Cellular Dynamics’ iCell Hepatocytes Enable Malaria-in-a-Dish Studies

MADISON, Wis., Feb. 11, 2015 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL) today announced that its iCell® Hepatocytes, or human liver cells manufacturedREAD MORE…

Gaumard Announces Latest Installations of Victoria Birthing Simulator in U.S.

Healthcare Educators Cite Innovation and Gaumard’s Record of Customer Support in Selection of Victoria MIAMI, Feb. 11, 2015 – Gaumard ScientificREAD MORE…

Great Basin Initiates Clinical Trial for Shiga Toxin-Producing E. coli Molecular Diagnostic Test

SALT LAKE CITY, Feb. 12, 2015 /PRNewswire/ — Great Basin Scientific, Inc. (NASDAQ: GBSN), today announced it has initiated a clinical trial for itsREAD MORE…

Novavax Announces Initiation of Ebola Vaccine Phase 1 Clinical Trial Supported by Non-Human Primate Challenge Data and Documented Rapid Manufacturing Capabilities

GAITHERSBURG, Md., Feb. 12, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinantREAD MORE…

Sunshine Heart, Inc. Secures Up to $10 Million in Growth Capital From Silicon Valley Bank

EDEN PRAIRIE, Minn., Feb. 19, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) (the “Company” or “Sunshine Heart”) today announced that it has entered into a loanREAD MORE…

Catalyst Pharmaceuticals Announces Appointment of Richard J. Daly and Donald A. Denkhaus to Its Board of Directors

CORAL GABLES, Fla., Feb. 19, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focusedREAD MORE…

CombiMatrix Announces Payor Contract With Fortified Provider Network

IRVINE, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatalREAD MORE…

Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosingREAD MORE…

Ocata Therapeutics to Present at 2015 Cowen Health Care Conference

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that thatREAD MORE…

Gaumard to Demonstrate Use of HAL Tetherless Simulators at EMS Today

BALTIMORE, Feb. 24, 2015 /PRNewswire/ — Gaumard(R) Scientific Company today announced it will showcase Trauma HAL(R) andNewborn HAL at EMS Today, the JEMS Conference & Exposition, Feb.READ MORE…

Puma Biotechnology to Present at Cowen Health Care Conference

LOS ANGELES, Calif., Feb. 24, 2015 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H.READ MORE…

Sunshine Heart to Present at the Cowen and Company 35th Annual Health Care Conference on March 4, 2015

EDEN PRAIRIE, Minn., Feb. 24, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that Chief Executive Officer, DaveREAD MORE…

Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; OTCBB: OCAT), a leader in the field of Regenerative OphthalmologyTM, todayREAD MORE…

Sunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal Trial of C-Pulse(R) Heart Assist System

EDEN PRAIRIE, Minn., Feb. 25, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) today announced it has received unconditional approval from the FDA to conduct anREAD MORE…

Gaumard Scientific Provides Update on U.S. Installations of Victoria Birthing Simulator

MIAMI, Feb. 25, 2015 /PRNewswire/ — Gaumard(R) Scientific Company today provided an update on installations of the Victoria(TM) birthing simulator at health care and educational facilitiesREAD MORE…

Ocata Therapeutics Approved for Listing on NASDAQ

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, todayREAD MORE…

Life Science Leader: Sucampo’s Declaration Of Independence

Signing a deal can seal your fate. An exit for your investors may mean the end of your dream. WhatREAD MORE…

Victoria birthing simulator featured on KSHB-NBC

KANSAS CITY, Mo. – A local pregnant woman will give birth hundreds of times just so local college students canREAD MORE…

Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development

LOS ANGELES, Feb. 27, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for theREAD MORE…

Trauma HAL simulator featured on WJZ-CBS: New Mannequin Helps First Responders Save Lives

BALTIMORE (WJZ) — A life-saving tool has a life of its own. Creators of the Trauma Hal mannequin unveiled itREAD MORE…

An End to Blindness?

AARP Bulletin Peter Jaret March, 2015 If you had seen Lisa Kulik and her husband strolling the grounds of theREAD MORE…

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

CALGARY, March 4, 2015 /CNW/ – Resverlogix Corp. (TSX:RVX) (the “Company”) today announced that it has completed a collaborative research programREAD MORE…

Boston Business Journal: ACT changes name to Ocata, earns listing on the Nasdaq

Don Seiffert Mar 4, 2015 A two decade-old biotech firm once at the center of worldwide debate over human cloningREAD MORE…

Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio

PASADENA, Calif., March 5, 2015 — Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announcedREAD MORE…

BioSpace: Booming PTC Therapeutics (PTCT) Means Job Openings

Riley McDermid Mar. 3, 2015 Martin Rexroad is senior vice president of human resources at a pharmaceuticals company focused on theREAD MORE…

Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for Treatment of Congenital Myasthenic Syndromes

CORAL GABLES, Fla., March 5, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focusedREAD MORE…

StemCells, Inc. to Participate at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference

NEWARK, Calif., March 10, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that Management will make a presentation on the Company’s programs andREAD MORE…

Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage

LOS ANGELES, Calif., Mar. 10, 2015 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiationREAD MORE…

Syndax to Participate in Two Upcoming Conferences

WALTHAM, Mass., March 12, 2015 — Syndax Pharmaceuticals, Inc., today announced that Arlene Morris, president and chief executive officer, willREAD MORE…

Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that theREAD MORE…

Ocata Therapeutics featured in Popular Science: YES, YOU CAN REVERSE DISEASE

Cassandra Willyard Mar 16, 2015 Certain maladies march forward through time, growing progressively more devastating. Now, scientists can turn backREAD MORE…

Innocoll AG Appoints James Tursi, M.D., as Chief Medical Officer

THLONE, Ireland, March 18, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL) today announced that James Tursi, M.D., has been appointed chief medical officer. Dr. Tursi willREAD MORE…

Philadelphia Business Journal: Penn and PTC Therapeutics team up to research rare diseases

PTC Therapeutics Inc. has formed an orphan disease research collaboration with the Perelman School of Medicine at theUniversity of Pennsylvania. TheREAD MORE…

Cyclacel’s CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015

BERKELEY HEIGHTS, N.J., March 20, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

NEWARK, Calif., March 24, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of theREAD MORE…

Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from Allele Biotechnology and Extends Leadership Position in Cell Therapy Capabilities

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that itREAD MORE…

Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan

SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s PhaseREAD MORE…

Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the companyREAD MORE…

Pivotal Pharmacokinetic Study of Innocoll’s XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain

ATHLONE, Ireland, April 1, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceuticalREAD MORE…

Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab(TM) in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference

NORWOOD, MA — (Marketwired) — 04/01/15 — Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), a clinical stage drug development company focusedREAD MORE…

Medical Device Daily: Immunexpress vying for FDA clearance of its sepsis test

Omar Ford Apr 6, 2015 When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen.READ MORE…

Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

LEXINGTON, Mass., April 6, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Resverlogix Receives Two Patents for RVX-208 in China

CALGARY, April 7, 2015 /CNW/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces that it has received two ChinaREAD MORE…

Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States Patent and Trademark Office

SAN DIEGO and WOODCLIFF LAKE, N.J., April 7, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc., announced today that the US Patent and TrademarkREAD MORE…

StemCells, Inc. to Participate at the 14th Annual Needham Healthcare Conference

NEWARK, Calif., April 7, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., will make a presentation on theREAD MORE…

SUCAMPO ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 14TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE

BETHESDA, Md., April 7, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast itsREAD MORE…

Gaumard Scientific Reports Latest U.S. Installations of Victoria Birthing Simulator

MIAMI, April 9, 2015 /PRNewswire/ — Gaumard (R) Scientific Company today provided an update on recent installations of the Victoria (TM) birthing simulator at U.S. healthREAD MORE…

New England Journal of Medicine Article Supports Importance of Follow-up Diagnostic Testing Following Positive Noninvasive Prenatal Screening Test

IRVINE, Calif., April 10, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based diagnostic servicesREAD MORE…

Great Basin Reports 101 U.S. Customers to End First Quarter, Reaffirms Guidance for 2015 Customer Acquisition

SALT LAKE CITY, April 13, 2015 /PRNewswire/ — Great Basin Scientific, Inc. (NASDAQ: GBSN; GBSNU), a molecular diagnostics company, today announcedREAD MORE…

Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market

NORWOOD, MA — (Marketwired) — 04/13/15 — Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development companyREAD MORE…

Curis Announces Presentation of Data From CUDC-427 and IRAK-4 Programs at AACR Annual Meeting

LEXINGTON, Mass., April 14, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients

LOS ANGELES, Calif., April 14, 2015 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has expanded theREAD MORE…

Catalyst Pharmaceuticals Announces Oral Presentation of Firdapse Phase 3 Trial Data at American Academy of Neurology Annual Meeting (AAN)

CORAL GABLES, Fla., April 14, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focusedREAD MORE…

Strand Life Sciences Names Scott Storrer to Expanded Leadership Position of Global President and Introduces U.S. Management Team

BANGALORE, India and AURORA, Colo., April 15, 2015 /PRNewswire/ — Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology toREAD MORE…

StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury

Proof-of-Concept Study Designed to Measure Improvement in Motor FunctionNEWARK, Calif., April 16, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leadingREAD MORE…

CombiMatrix Launches Buccal Swab DNA Collection as Alternative to Blood Draws for Postnatal Genetic Testing

IRVINE, Calif., April 16, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based diagnostic servicesREAD MORE…

Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market

NORWOOD, MA–(Marketwired – Apr 16, 2015) –Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical stage drug development company focused on theREAD MORE…

The Denver Post: Strand Life Sciences opens U.S. headquarters at Fitzsimons in Aurora

Alicia Wallace Apr 15, 2015 Bangalore, India-based Strand, which developed a genetic sequencing test that analyzes cancer tumors and providesREAD MORE…

Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System

EDEN PRAIRIE, Minn., April 16, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the U.S. Food andREAD MORE…

Cempra to Present at Two Upcoming Scientific Conferences

CHAPEL HILL, N.C., April 17, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibioticsREAD MORE…

Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds

BERKELEY HEIGHTS, N.J., April 20, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announcedREAD MORE…

Boston Business Journal: Bay State’s newest Nasdaq-listed biotech, Corbus gets $5M cystic fibrosis award

A year ago today, Corbus Pharmaceuticals didn’t exist. Today, it’s publicly-traded on the Nasdaq and planning to launch a mid-stageREAD MORE…

Great Basin Receives FDA 510(k) Clearance for Group B Strep Molecular Diagnostic Test

Salt Lake City, April 22, 2015 — Great Basin Scientific, Inc. (NASDAQ: GBSN and GBSNU), a molecular diagnostics company, todayREAD MORE…

Cystic Fibrosis Foundation Therapeutics Announces $5 Million Award to Support Development of Anti-Inflammatory Treatment

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million developmentREAD MORE…

GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute

LOUISVILLE, CO–(Marketwired – April 22, 2015) – GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigateREAD MORE…

StemCells, Inc. to Participate at the Inaugural World Medical Innovation Forum

NEWARK, Calif., April 27, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., willREAD MORE…

Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL

DOYLESTOWN, Pa., April 27, 2015 /PRNewswire/ — Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curativeREAD MORE…

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

CALGARY, April 27, 2015 /CNW/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announced that it  has entered intoREAD MORE…

Gaumard to Feature Victoria Birthing Simulator at ACOG Annual Clinical and Scientific Meeting

MIAMI, April 28, 2015 /PRNewswire/ — Gaumard(R) Scientific Company (www.gaumard.com) today announced it will feature theVictoria(TM) birthing simulator at the AmericanREAD MORE…

Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to Deliver Opening Address at the Massachusetts State Science & Engineering Fair

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced thatREAD MORE…

Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371

SAN DIEGO, April 29, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascendingREAD MORE…

Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the publication ofREAD MORE…

Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that aREAD MORE…

Envarsus® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDAREAD MORE…

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completedREAD MORE…

Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Treatment of Rheumatoid Arthritis, Meets Primary Endpoint in Follow-On Phase 2b Clinical Trial

BOTHELL, Wash., May 5, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced thatREAD MORE…

SUCAMPO AND HARBIN GLORIA PHARMACEUTICALS ENTER INTO LICENSING AGREEMENT FOR AMITIZA(R) (LUBIPROSTONE) IN CHINA

BETHESDA, Md., May 11, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced thatREAD MORE…

Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief ExecutiveREAD MORE…

Gaumard Scientific Continues U.S. Roll-Out of Most Advanced Birthing Simulator, Victoria, at Health Care Educational Institutions

MIAMI, May 13, 2015 /PRNewswire/ — Gaumard(R) Scientific Company (www.gaumard.com) today provided an update on U.S. installations of the Victoria(TM) birthingREAD MORE…

SUCAMPO ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 2015 UBS GLOBAL HEALTHCARE CONFERENCE

BETHESDA, Md., May 13, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the release of four abstracts on itsREAD MORE…

Strand Life Sciences Introduces Scientific Advisory Board

AURORA, Colo., May 13, 2015 – Strand Life Sciences, a global genomic profiling company that uses next-generation sequencing technology toREAD MORE…

Strand Life Sciences to Highlight Clinical Utility Data for StrandAdvantage at 2015 ASCO Annual Meeting

AURORA, Colo., May 14, 2015 – Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technologyREAD MORE…

StemCells, Inc. Announces Positive Top-Line Results of Its Thoracic Spinal Cord Injury Phase I/II Study

NEWARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics forREAD MORE…

Corbus Pharmaceuticals Appoints Charles N. Serhan, Ph.D., to Scientific Advisory Board

NORWOOD, MA — (Marketwired) — 05/14/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the “Company”), a clinical stage drug developmentREAD MORE…

Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society

BOTHELL, Wash., May 15, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-1 Phase 3 Study for the Treatment of Diabetic Foot Infection

ATHLONE, Ireland, May 15, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufacturesREAD MORE…

StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference

NEWARK, Calif., May 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that management will make a presentation on theREAD MORE…

Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that PaulREAD MORE…

Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, life-threatening chronicREAD MORE…

Cynapsus Therapeutics Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation

Cynapsus Therapeutics Inc. announced today the filing of a registration statement with the US Securities and Exchange Commission relating toREAD MORE…

Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired Bacterial Pneumonia at the American Thoracic Society Conference

CHAPEL HILL, N.C., May 19, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibioticsREAD MORE…

Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)

Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting orREAD MORE…

Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

LEXINGTON, Mass., May 20, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Opexa Therapeutics to Present at the 2015 Marcum Microcap Conference

THE WOODLANDS, Texas–(BUSINESS WIRE)– Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosisREAD MORE…

Forbes: The Family-Run Company That’s Making Super Sophisticated “Robot” Patients

At a factory on the south side of Miami, Florida, teams of engineers are building critical tools for training newREAD MORE…

Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced thatREAD MORE…

Arena Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference

SAN DIEGO, May 26, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present aREAD MORE…

Cempra to Present at the Jefferies 2015 Global Healthcare Conference

CHAPEL HILL, N.C., May 26, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibioticsREAD MORE…

Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF(TM) US Pivotal Study for C-Pulse(R) Heart Assist System

EDEN PRAIRIE, Minn., May 26, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) is pleased to announce that the USREAD MORE…

GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients

LOUISVILLE, CO–(Marketwired – May 27, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) today announced top line results from the GS-4774 PhaseREAD MORE…

Sucampo Announces Webcast of Its Presentation at the Jefferies 2015 Healthcare Conference

BETHESDA, Md., May 27, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Strand Life Sciences Set to Introduce Expanded StrandAdvantage Genomic Profiling Service at 2015 ASCO Annual Meeting

AURORA, Colo., May 27, 2015 – Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technologyREAD MORE…

Biospace: Corbus Will Interview Twice as Many Candidates in 2015 as Its Ranks Grow

Yuval Cohen is the chief executive officer of Corbus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focusing on rare, life-threatening,READ MORE…

Health Care Educators Continue to Select Gaumard Scientific’s Victoria as Preferred Birthing Simulator for Simulation Centers

MIAMI, June 1, 2015 /PRNewswire/ — Gaumard® Scientific Company (www.gaumard.com) today announced that its U.S. installations of the Victoria™ birthing simulatorREAD MORE…

Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that itREAD MORE…

Apogenix appoints Peter Willinger as new CFO

HEIDELBERG, Germany, June 3, 2015 /PRNewswire/ — Apogenix, a next generation immuno-oncology company, announced today the appointment of Peter Willinger asREAD MORE…

StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical Spinal Cord Injury

NEWARK, Calif., June 4, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-basedREAD MORE…

Corbus Pharmaceuticals Expands Clinical Development of Resunab™ with a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis

NORWOOD, MA — (Marketwired) — 06/05/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA

CALGARY, June 8, 2015 /CNW/ – Resverlogix Corp. (TSX: RVX) today announced that findings of a study performed by theREAD MORE…

Gaumard Scientific to Launch Industry’s Most Advanced Newborn Simulator, Newborn Tory, at AWHONN 2015 Convention

MIAMI, June 8, 2015 – Gaumard® Scientific Company today announced that it will launch Newborn Tory (TM) S2210, the industry’s mostREAD MORE…

Gaumard to Offer Preview of Newborn Tory at INACSL Alongside Demonstrations of Victoria and Gaumard’s Comprehensive Family of Patient Simulators

MIAMI, June 9, 2015 /PRNewswire/ — Gaumard (R) Scientific Company today announced that it will offer a preview of NewbornREAD MORE…

GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring

LOUISVILLE, CO–(Marketwired – June 10, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) today announced that it is evaluating strategic options forREAD MORE…

Arrowhead Receives Orphan Drug Designation for ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the United StatesREAD MORE…

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-2 Phase 3 Study for the Treatment of Diabetic Foot Infection

ATHLONE, Ireland, June 15, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range ofREAD MORE…

NOVAVAX ANNOUNCES MANAGEMENT PROMOTION

GAITHERSBURG, Md., June 15, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

CHINA FOOD AND DRUG ADMINISTRATION ACCEPTS IND FOR PIVOTAL STUDY OF AMITIZA(R) (LUBIPROSTONE)

BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced thatREAD MORE…

HIGH-TECH MANIKIN GIVES STUDENTS HANDS-ON TRAINING IN CHILDBIRTH

LOS ANGELES (KABC) –A high-tech true-to-life manikin mother is about to deliver a baby and ABC7 health specialist Denise DadorREAD MORE…

Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that its ClinicalREAD MORE…

Boston Herald: Norwood company tests immune reset drug

A Norwood pharmaceutical company is launching three phase-two studies this summer to test a medication for illnesses that cause debilitatingREAD MORE…

UT San Diego: San Diego biotech visits Philly

Bradley Fikes June 17, 2015 I wasn’t able to attend this year’s Biotechnology Industry Organization convention this year. But othersREAD MORE…

StemCells, Inc.’s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada

NEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-basedREAD MORE…

NOVAVAX APPOINTS GAIL BOUDREAUX TO BOARD

GAITHERSBURG, Md., June 18, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that CompanyREAD MORE…

NOVAVAX RECOGNIZED BY WASHINGTON POST AS TOP WORKPLACE

GAITHERSBURG, Md., June 19, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Biotech convo: A look ahead

This year’s Biotechnology Industry Organization’s convention in Philadelphia was on familiar ground for Joe Panetta, CEO of San Diego-based Biocom,READ MORE…

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

CALGARY, June 22, 2015 /CNW/ – Resverlogix Corp. (TSX: RVX) today announced that following recent meetings with various European regulatory bodies,READ MORE…

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

The war against Alzheimer’s disease has been a brutal, losing fight. Those stricken with the disease, their loved ones, andREAD MORE…

Ocata Therapeutics Announces Positive Results Reported in a Late Breaking Abstract at the Annual Meeting of the International Society for Stem Cell Research

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today thatREAD MORE…

Catalyst Pharmaceuticals Announces Encouraging Top-Line Results in Proof-of-Concept Trial of Vigabatrin in Patients With Treatment-Refractory Tourette’s Disorder

CORAL GABLES, Fla., June 24, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

CombiMatrix Expands Sales Team to Accelerate Entry Into New Markets

IRVINE, Calif., June 25, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based diagnostic servicesREAD MORE…

Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders

TORONTO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company”) today announced that it presented data fromREAD MORE…

Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

SAN DIEGO, June 25, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced pre-treatment biomarker and histology data fromREAD MORE…

StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration

NEWARK, Calif., June 26, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics forREAD MORE…

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis

DUNDEE, UK and ROSCOFF, France, June 29, 2015 (GLOBE NEWSWIRE) — Cyclacel Ltd, a wholly owned subsidiary of Cyclacel Pharmaceuticals,READ MORE…

Catalyst Pharmaceuticals Joins Russell 2000, 3000 and Global Indexes

CORAL GABLES, Fla., June 29, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that theREAD MORE…

Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection

ATHLONE, Ireland, June 30, 2015 (GLOBE NEWSWIRE) — Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufacturesREAD MORE…

Catalyst Pharmaceuticals Appoints Dr. Gary Ingenito as Chief Medical Officer

CORAL GABLES, Fla., June 30, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Pharnext’s PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting

PARIS, June 30, 2015, Pharnext SAS today announced that data related to its lead pleodrug PXT-3003, being developed for theREAD MORE…

Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product

AURORA, Colo. and BANGALORE, India, July 1, 2015 – Strand Life Sciences, a global genomic profiling company that uses nextREAD MORE…

StemCells, Inc. to Participate at Cantor Fitzgerald’s Inaugural Healthcare Conference

NEWARK, Calif., July 1, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that management will make a presentation on theREAD MORE…

Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosedREAD MORE…

First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing’s Disease, a Serious Endocrine Disorder

BERKELEY HEIGHTS, N.J., July 2, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial

CHAPEL HILL, N.C., July 7, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibioticsREAD MORE…

Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it receivedREAD MORE…

Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis

NORWOOD, MA — (Marketwired) — 07/13/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative OphthalmologyTM, announced today thatREAD MORE…

Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer’s Disease

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ – Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinicalREAD MORE…

Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues toREAD MORE…

Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China

Heidelberg, Germany, July 15, 2015 – Apogenix, a next generation immuno-oncology company, announced today that it has entered into anREAD MORE…

SiteOne Therapeutics Secures Investment from Bozeman-based Next Frontier Capital

BOZEMAN, MONTANA, July 15, 2015 — SiteOne Therapeutics Inc. today announced the completion of an investment by Next Frontier Capital,READ MORE…

StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration

NEWARK, Calif., July 20, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-basedREAD MORE…

The big gamble: Catalyst Pharmaceuticals of Coral Gables bets on new drug for rare disease

Miami Herald JOSEPH A. MANN JR. July 18, 2015 About six years ago, Lisa Rountree, 45, a mother of twoREAD MORE…

Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference

GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

StemCells, Inc. Announces Webcast to Discuss Second Quarter 2015 Financial Results

NEWARK, Calf., July 22, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-basedREAD MORE…

Sucampo Announces Second Quarter 2015 Earnings Call

BETHESDA, Md., July 22, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

HEIDELBERG, Germany, July 28, 2015 /PRNewswire/ — Apogenix, a next generation immuno-oncology company, announced today that it has entered intoREAD MORE…

International Stem Cell Corporation Announces 1:150 Reverse Stock Split

CARLSBAD, CA–(Marketwired – July 28, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases

SAN DIEGO, July 29, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in aREAD MORE…

Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP

GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Gaumard’s Latest UNI Operating System Update Adds Performance and New Functionality

MIAMI, July 30, 2015 – Gaumard® Scientific Company today announced that the latest update to UNI®, the world’s first operatingREAD MORE…